Arvinas extends cash runway to 2028, moves ARV-102 PSP trials to 2027

seekingalpha.com

Arvinas expects its cash runway to extend into the second half of 2028, while shifting its ARV-102 PSP trials to 2027. The company highlighted three strategic milestones in Q2 2026, including the first FDA approval of a PROTAC degrader, VEPPANU, and an out-licensing deal with Rigel. CEO Randy Teel noted these achievements mark significant progress, with pipeline timeline adjustments reflecting a focus on long-term financial stability and development priorities.


With a significance score of 1.6, this news ranks in the top 31% of today's 33437 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Arvinas extends cash runway to 2028, moves ARV-102 PSP trials to 2027 | News Minimalist